

# TABLE OF CONTENTS

June 29, 2009

No. 2145

## BUSINESS

- 1 Glufast, Urief to Drive Kissei's Growth: Dr Ajisawa  
- Accelerating R&D of Biosimilars
- 2 Eli Lilly Japan to Increase Sales of Anticancer Drugs to 30% of Total Sales
- 3 Injectable Risperdal to Change Treatment of Schizophrenia: Janssen
- 3 Distribution Business Reform in FY2008 Was Failure: Mr Matsutani
- 4 Zithromac Leaps to Top Place in April: Rep Track Survey
- 4 **TOPICS**
  - Female MRs Should Exercise More Leadership: Mr Sekiguchi
  - Baxter Selected as One of the World's Most Ethical Companies, 100 Best US Corporate Citizens
- 6 **BUSINESS NEWS IN BRIEF**
  - Sanofi-aventis to Lead Diabetes Drug Market with Apidra
  - ASKA Takes Over 5 Products from Wyeth
  - Toyobo Develops New Expression Vector to Manufacture Antibody Pharmaceuticals at High Yield
  - Takeda Launches New Dosage Combinations of Blopress in Europe
  - Ono to Transfer Licensing Activities to the US
  - Eisai Sets Up New Marketing Subsidiary in Austria
  - MSs to Be Allowed to Take MR Certification Exam
- 7 **Statistics**
  - Sales of Ethical Drugs Up 0.2% in April

## REGULATORY

- 8 Range of Drugs Eligible for Price Protection Proposed by FPMAJ Is Reasonable: Report
  - Prices Should Be Protected for 15 Years
  - Discontinue Automatic Re-Pricing Following Market Expansion
  - Stop Additional Price Cuts for Long-Listed Original Drugs
  - New Pricing Rule Needed for Biosimilars
- 9 Revised Pricing Rule Had Little Effect on Pricing of New Drugs in FY2008: FPMAJ
- 9 New Dosage, Treatment Regimens Expected to Become Patentable
  - Patentability to Encourage R&D
- 10 Patents on New DDS Formulations with Known API, Indications May Become Eligible for Patent Period Restoration
- 11 Various Intellectual Properties Should Be Used for Lifecycle Management: Prof. Yamana
- 11 DSUR (E2F) Fails to Reach Step 4 in Yokohama: ICH
- 12 **REGULATORY NEWS IN BRIEF**
  - Astellas, Pfizer Obtain Additional Indications for Celecox
  - Medet Monotherapy for Type 2 Diabetes Approved
- 13 **Commentary**
  - Additional Price Cuts for Long-listed Original Drugs

## NEWPRODUCTS

- 12 - Asahi Kasei Medical: Planova BioEX

## R&D

- 14 Top Quark to Create New CRO to Undertake Asian Trials
- 14 Japan Participates in Multinational PIII Study of JAK-3 Inhibitor: Pfizer
- 15 **R&D NEWS IN BRIEF**
  - ZERIA's Z-338 Seems to Be Effective for FD
  - KW-6002 Improves Motor Complications in PD: Kyowa Kirin
  - Novartis Presents Data on Over 15 Compounds at ASCO
  - BSI-201 Prolongs Survival in TNBC
  - Linagliptin Reduces HbA1c, FPG
- 17 **Commentary**
  - Clinical Applications of ADCs Coming Closer to Reality
- 16 **TOPICS**
  - JACDS Approves Tadayuki Teranishi as New President

## SELF-MEDICATION

- 18 Sales of Class 1 OTC Drugs Down Following Full Implementation of Amended PAL: JACDS
- 18 **SELF-MEDICATION NEWS IN BRIEF**
  - In-House Formulation Containing Minoxidil at 7% Prescribed by Clinics
  - 63% of Drs Concerned about Delay in Discovering Serious Illness due to Use of More OTC Drugs

## OPINION

- 19 - High Price for Executive Search in Japan: Philip Carrigan

## GENERICS

- 20 45 Univ. Hospitals to Consider Joint Purchases
- 20 **GENERICS NEWS IN BRIEF**
  - 56.1% of Prescriptions Permit Use of Generics: FPMAJ Survey
  - Generics of Imaging Agents, Antibacterials, Anticancer Agents Have Great Economic Effects: Prof. Koyama

## MEDICAL FACILITIES & NURSING CARE

- 21 Prof. Kudo Calls For Proper Use of Nexavar for HCC
- 21 Sorafenib May Be Used in Wide Range of Patients
- 22 Tamiflu Is Not Ineffective against Resistant Viruses
- 22 Pandemic of New-Type Flu Infections Unavoidable in Japan in Oct-Nov: Prof. Oshitani
- 23 Memantine Dosage Titration Necessary in Patients with Renal Disorders
- 23 **TOPICS**
  - Expert Committee Recommends HbA1C for Diagnosis of Diabetes